Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
donafenib + lenvatinib + apatinib
- Development stage
- Unknown
- Lead developer
- Suzhou Zelgen Biopharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
donafenib + lenvatinib + apatinib is a combination of three small-molecule multi-kinase inhibitors used in the treatment of hepatocellular carcinoma (HCC). This combination is specifically highlighted in clinical trial contexts (such as NCT05523609) where these agents serve as the targeted therapy component of a multimodal regimen including hepatic arterial infusion chemotherapy (HAIC) and PD-1 inhibitors (e.g., sintilimab, camrelizumab, or tislelizumab). Donafenib, a deuterated sorafenib derivative, targets Raf kinases and VEGFR; lenvatinib targets VEGFR1-3, FGFR1-4, PDGFRα, KIT, and RET; and apatinib (rivoceranib) is a highly selective inhibitor of VEGFR-2. Together, these agents provide comprehensive inhibition of angiogenesis and tumor cell signaling pathways to treat postoperative HCC with microvascular invasion (MVI).
- Brand names
- Zepaton
- Other names
- Rivoceranib
02
Targets
FGFR4 (Fibroblast growth factor receptor 4)PDGFRA (Platelet-derived growth factor receptor alpha)KIT (c-KIT proto-oncogene receptor tyrosine kinase)VEGFR2 (Vascular endothelial growth factor receptor 2)PDGFRB (Platelet-derived growth factor receptor beta)FGFR3 (Fibroblast growth factor receptor 3)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR3 (Vascular endothelial growth factor receptor 3)RAF1 (c-Raf-1 (Y340D/Y341D))FGFR2 (Keratinocyte growth factor receptor)FGFR1 (Fibroblast growth factor receptor 1)RET (Rearranged during transfection receptor tyrosine kinase)FLT3 (Fms related receptor tyrosine kinase 3)
Beyond the preview
Go deeper on donafenib + lenvatinib + apatinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on donafenib + lenvatinib + apatinib.